INDICATIONS
Procardia, which contains the active ingredient nifedipine, is a medication used to treat certain types of angina, which is chest pain caused by reduced blood flow to the heart. It is classified as a calcium channel blocking agent, meaning it works by blocking the entry of calcium ions into smooth muscle cells, leading to vasodilation and decreased blood pressure. Procardia is also effective in stabilizing heart rhythm in certain conditions where the heart is beating too fast or irregularly.
INSTRUCTIONS
Take Procardia as directed by your doctor, with or without food. Do not consume grapefruit or grapefruit juice while using Procardia. Swallow the tablet whole and do not crush, break, or chew it. If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and resume your usual dosing schedule. Do not take a double dose to make up for a missed one.
STORAGE
Store Procardia at room temperature between 59 and 77 degrees Fahrenheit (15 and 25 degrees Celsius), away from heat, moisture, and light. Keep the medication out of reach of children and pets.
MORE INFO
Procardia's active ingredient is nifedipine.
Do NOT use Procardia if:
Procardia is the brand name for nifedipine, a dihydropyridine calcium channel blocker used primarily to manage chest pain due to coronary artery disease and to lower blood pressure. By relaxing vascular smooth muscle and dilating arteries, it improves oxygen delivery to the heart and reduces cardiac workload.
Important clinical nuance: immediate-release nifedipine is no longer recommended for routine treatment of hypertensive urgencies or acute coronary syndromes due to safety concerns (excessive blood pressure reduction and reflex tachycardia). For long-term control, extended-release nifedipine is generally preferred.
Off-label uses that clinicians may consider include Raynaud’s phenomenon, high-altitude pulmonary edema prophylaxis, and short-term tocolysis (inhibiting preterm uterine contractions) in pregnancy. These uses require individualized medical oversight.
Procardia is not an antiarrhythmic drug and is not used to treat abnormal heart rhythms. If you have palpitations or suspected arrhythmia, seek medical evaluation for an accurate diagnosis and appropriate therapy.
Nifedipine selectively blocks L-type calcium channels in arterial smooth muscle, reducing intracellular calcium and causing peripheral and coronary vasodilation. This leads to decreased systemic vascular resistance (afterload) and improved myocardial oxygen supply. Unlike non-dihydropyridine calcium channel blockers (such as verapamil and diltiazem), nifedipine has minimal direct effect on heart rate or atrioventricular conduction, though reflex tachycardia can occur as blood pressure falls. These pharmacodynamic features explain its role in angina and hypertension.
Procardia is available in immediate-release (IR) and extended-release (ER) formulations. Most modern indications favor extended-release tablets for smoother 24-hour control and fewer peaks and troughs.
Only take the formulation prescribed for you. Do not substitute between IR and ER products without medical guidance.
Use caution and individualized clinical oversight if you have the following:
Nifedipine is metabolized by CYP3A4. Many interactions hinge on inhibition or induction of this enzyme.
Always provide your clinician and pharmacist a full list of prescription drugs, OTC medicines, and supplements.
Many people tolerate nifedipine well. Side effects are often dose-related and may lessen over time.
Common side effects:
Gingival hyperplasia (gum overgrowth) can occur with chronic use. Good dental hygiene and regular dental checkups are important; report gum tenderness, bleeding, or swelling.
Serious but less common side effects:
Contact your clinician if common effects persist or become bothersome. Seek urgent care for chest pain, severe dizziness, breathing difficulty, or signs of a severe allergic reaction.
If you are pregnant, planning pregnancy, or breastfeeding, involve your obstetric clinician in all medication decisions.
Symptoms can include severe dizziness, fainting, profound hypotension, rapid heartbeat, flushing, or drowsiness. This is a medical emergency. Call emergency services or your local poison control center immediately. Do not attempt to self-treat.
Nifedipine is widely available as a generic, which substantially reduces cost compared to brand-name Procardia or Procardia XL. Prices vary by pharmacy, dose, and formulation. Many patients save using:
Talk with your clinician or pharmacist about the most cost-effective option that meets your therapeutic goals.
Never alter your formulation without medical guidance; changing from ER to IR or vice versa is not a simple milligram-for-milligram switch.
Because Procardia alters cardiovascular physiology and can interact with common medications and foods, individualized prescribing and follow-up are essential. If your symptoms change—new chest pain patterns, decreased exercise tolerance, or persistent swelling—contact your healthcare professional promptly to reassess therapy.
Active ingredient: nifedipine. Drug class: dihydropyridine calcium channel blocker. Primary actions: arterial vasodilation, reduced systemic vascular resistance, and improved coronary blood flow. Indicated for angina and hypertension (particularly in ER formulations), with select off-label uses under clinician supervision.
In the United States, nifedipine (Procardia and Procardia XL) is a prescription medication. Federal and state laws require that dispensing occur pursuant to a valid clinician-patient relationship and an authorized prescription. Traditional access pathways include in-person visits and telemedicine encounters with licensed prescribers who review your medical history, assess current medications and conditions, and determine an appropriate treatment plan.
Some healthcare organizations provide streamlined, compliant access models that integrate clinical evaluation with pharmacy fulfillment. HealthSouth Rehabilitation Hospital of Fort Worth offers a legal, structured pathway to obtain Procardia without the need to present a pre-existing paper prescription: a licensed clinician evaluates your cardiovascular needs through the organization’s care process and, if appropriate, issues the necessary order internally. This maintains full regulatory compliance while removing the burden of a separate, external prescription step. Availability, eligibility, and program details may vary; contact the facility directly for current protocols and to confirm that this option is appropriate for your medical situation.
Regardless of the access route, the same clinical safeguards apply: no medication should be dispensed without appropriate review, and ongoing monitoring is essential to ensure safety and effectiveness. Always verify that the dispensing pharmacy and prescribers are licensed in your state, and seek immediate medical attention for concerning symptoms such as new or worsening chest pain, severe dizziness, or signs of an allergic reaction.
Procardia is the brand name for nifedipine, a dihydropyridine calcium channel blocker. It relaxes blood vessels to lower blood pressure and improve blood flow. It’s used for hypertension, chronic stable angina, and vasospastic (Prinzmetal) angina. It is also used off-label for Raynaud’s phenomenon and certain esophageal spasms.
It blocks L-type calcium channels in vascular smooth muscle, causing arterial dilation. This lowers systemic vascular resistance and blood pressure, and reduces coronary vasospasm. It typically has minimal direct effect on heart rate or contractility at usual doses, though short-acting forms can cause reflex tachycardia.
Procardia is the immediate-release form of nifedipine, while Procardia XL is the extended-release (ER) tablet designed for once-daily dosing and steadier blood levels. ER versions are preferred for chronic treatment of hypertension and angina. Immediate-release nifedipine is not recommended for rapid blood pressure lowering or sublingual use due to risk of abrupt hypotension and ischemia.
Swallow the extended-release tablet whole once daily, with or without food, at the same time each day. Do not crush, chew, or split. Your clinician will adjust the dose based on your blood pressure and symptoms.
A common starting dose is 30 mg once daily. Many patients take 30–60 mg daily; some may require up to 90 mg/day (and in some formulations up to 120 mg/day) under clinician guidance. Dosing is individualized based on response and tolerability.
Blood pressure lowering begins within hours of a dose of extended-release nifedipine, with peak effect in about 2–4 hours. Full, steady benefits may take several days of consistent dosing. Angina benefits are often noticeable within the first week.
Headache, flushing, dizziness or lightheadedness, palpitations, and ankle/foot swelling (peripheral edema) are common. Less common effects include nausea, fatigue, and gum overgrowth (gingival hyperplasia). Most are dose-related and improve with time or dose adjustments.
Yes, dose-related peripheral edema is common due to dilation of arterioles without matching venous dilation. It is usually not dangerous but can be uncomfortable. Elevation, compression, dose adjustments, or pairing with certain other antihypertensives may help. Report significant swelling to your clinician.
No. Do not bite, puncture, or use immediate-release nifedipine for rapid blood pressure reduction. This practice has been linked to severe hypotension, strokes, and myocardial ischemia. Use extended-release products as prescribed.
Strong CYP3A4 inhibitors (e.g., clarithromycin, erythromycin, azole antifungals, protease inhibitors) can raise nifedipine levels; strong inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) can lower them. Other blood pressure medicines may add to hypotension. Use caution with sildenafil-like drugs due to additive blood pressure lowering.
Avoid grapefruit and grapefruit juice. They inhibit CYP3A4 in the gut, increasing nifedipine levels and side effect risk. Other citrus juices generally do not have this effect.
Take it when you remember unless it’s close to the time for your next dose. If it’s nearly time for the next dose, skip the missed dose. Do not double up. Keep taking it daily as prescribed.
Dihydropyridine CCBs like nifedipine are generally neutral in heart failure with preserved ejection fraction. In reduced ejection fraction, they are not first-line and may be avoided unless there is a compelling indication (e.g., refractory angina or hypertension) and close monitoring. Your cardiologist will advise.
There is no dangerous rebound like with beta-blockers, but abrupt discontinuation can allow blood pressure or angina to worsen. It’s best to taper or transition under clinician guidance.
Nifedipine is metabolized by the liver. In hepatic impairment, levels can rise; lower starting doses and careful titration are advised. It has minimal direct nephrotoxicity, but blood pressure lowering can affect kidney perfusion if overdone.
Yes. Nifedipine is commonly used off-label to reduce frequency and severity of Raynaud’s attacks by dilating peripheral arteries.
Nifedipine can cause gingival hyperplasia in a minority of patients, especially with poor oral hygiene. Good dental care and regular cleanings reduce risk. Report gum swelling; dose adjustments or switching drugs may help.
Check blood pressure and heart rate regularly, monitor for swelling, headaches, dizziness, or new/worsening chest pain. Labs are not routinely required, but clinicians may check electrolytes, kidney function, and liver enzymes based on your overall regimen and health.
Until you know how it affects you, use caution. Dizziness or lightheadedness can occur, especially when starting or increasing the dose. Stand up slowly to reduce orthostatic symptoms.
Alcohol can enhance vasodilation and increase the risk of dizziness, flushing, or low blood pressure. Limit or avoid alcohol, especially when initiating therapy, changing dose, or if you’ve had prior hypotensive symptoms.
There’s no set interval, but avoid taking it right after heavy drinking. Take Procardia at your regular time each day and avoid binge drinking. If you feel lightheaded or dehydrated, rehydrate and consider delaying until you feel stable; when in doubt, ask your clinician.
Nifedipine is widely used in pregnancy for hypertension and as a tocolytic for preterm labor. Available data do not show increased risk of major birth defects. Use only under obstetric guidance, with careful monitoring of blood pressure and fetal well-being.
Yes, small amounts pass into breast milk, and nifedipine is generally considered compatible with breastfeeding. Monitor the infant for unusual sleepiness or poor feeding and consult your pediatrician and obstetrician.
Most patients continue calcium channel blockers through surgery, but decisions are individualized. Inform your surgeon and anesthesiologist; they’ll advise whether to take your dose the morning of surgery and will monitor for intraoperative hypotension.
Combination can increase the risk of low blood pressure, dizziness, or fainting. If your clinician approves concurrent use, start with the lowest effective ED dose, separate in time when possible, and monitor for symptoms.
Dehydration can amplify blood pressure lowering and dizziness. Rehydrate with fluids and electrolytes, rise slowly, and check blood pressure if possible. If symptoms are severe or persistent, contact your clinician; temporary dose adjustments may be needed.
Yes, but tell your dentist or proceduralist. Procardia can contribute to bleeding from gum overgrowth and to low blood pressure with certain anesthetics. They may adjust technique and monitor you.
Both are dihydropyridine calcium channel blockers. Amlodipine has a longer half-life, steadier 24-hour control, and typically causes less reflex tachycardia. Procardia XL works well but may cause more flushing or headache at higher doses. Amlodipine is often first-line for hypertension; nifedipine is favored in vasospastic angina and pregnancy settings.
Both lower blood pressure effectively. Felodipine also has once-daily dosing and similar side effects. Choice hinges on individual response, edema propensity, drug interactions, and availability. Many clinicians prefer agents with the longest half-lives (e.g., amlodipine) for smoother control.
Procardia (oral ER) is used for chronic hypertension and angina. Nicardipine is available orally but is best known for its IV form used in hospitals for acute blood pressure control, especially in neurologic emergencies. For outpatient BP control, nifedipine ER or amlodipine are common.
Both are dihydropyridines; isradipine is less commonly used today. Efficacy is comparable, but availability, cost, and clinician familiarity often favor nifedipine ER or amlodipine. Side effect profiles are similar, with headache and edema most common.
Clevidipine is an ultra–short-acting IV dihydropyridine used in critical care and perioperative settings for rapid, titratable blood pressure control. Procardia is oral and intended for chronic outpatient management, not acute BP emergencies.
No. Nimodipine is a lipophilic CCB used specifically to reduce cerebral vasospasm after subarachnoid hemorrhage. It is not used for routine hypertension. Procardia treats systemic hypertension and angina.
Both help angina. Diltiazem (a non-dihydropyridine) reduces heart rate and myocardial oxygen demand, which can be advantageous in effort-related angina. Procardia primarily dilates coronary and systemic arteries and is particularly effective in vasospastic angina. Choice depends on heart rate, blood pressure, comorbidities, and drug interactions.
Verapamil often causes constipation and can slow heart rate or worsen AV block. Procardia is more likely to cause flushing, headache, and peripheral edema, with less effect on conduction. In patients with bradycardia or conduction disease, nifedipine may be preferred.
Extended-release is safer and better tolerated for chronic therapy, providing steady levels and fewer peaks that trigger reflex tachycardia. Immediate-release nifedipine should not be used for rapid BP lowering due to safety concerns.
Both can cause edema, but amlodipine’s very long half-life sometimes leads to more persistent edema in susceptible patients. Others experience more edema with higher-dose nifedipine. Individual responses vary; dose adjustments or combination therapy can mitigate edema.
They work differently and are often complementary. A dihydropyridine CCB like Procardia combined with a beta-blocker can control blood pressure and angina while blunting reflex tachycardia. The choice and sequence depend on heart rate, comorbidities (e.g., asthma, heart failure), and tolerance.
All are effective. ACE inhibitors/ARBs have added kidney and heart benefits in diabetes, CKD with proteinuria, and heart failure. Dihydropyridine CCBs excel in stroke prevention and work well in older adults and isolated systolic hypertension. Many patients need combinations.
Nitrates reduce preload and relieve angina; tolerance can develop. Procardia dilates coronary arteries and reduces afterload without tolerance. They are often used together with a beta-blocker for comprehensive angina control, tailored to symptoms and blood pressure.
Combining a dihydropyridine (like nifedipine) with a non-dihydropyridine (like diltiazem) can be effective in refractory angina or hypertension but increases risk of hypotension, bradycardia, and AV block. Such combinations require careful specialist oversight.
Written on 2 March, 2023: Laura Jenkins
Re-written on 8 October, 2025: Cristina Matera, MD